Denileukin diftitox (Ontak)

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Barbara Ann Karmanos Cancer Institute, Eisai Inc.

Conditions

CancerLeukemia, Adult T-CellMultiple Myeloma

Phase 1

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

TerminatedNCT01251952

Barbara Ann Karmanos Cancer InstituteMultiple Myeloma

Start: 2010-11-30End: 2013-05-31Updated: 2017-06-20

Phase 2

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

TerminatedNCT00117845

National Cancer Institute (NCI)Leukemia, Adult T-Cell

Start: 2005-07-11End: 2013-06-30Updated: 2019-11-19

Unknown Phase

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Eisai Inc.Cancer

Updated: 2015-01-26